Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  adenocarcinoma of the stomach
Stage/Subtype:  adenocarcinoma of the stomach
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 28 for your search:
Start Over
Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TO-TAS-102-302, NCI-2016-00338, 2015-002683-16, NCT02500043
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: EMR 100070-007, NCI-2016-00646, 2015-003300-23, NCT02625610
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA224-020, NCI-2014-00315, 2014-002605-38, NCT01968109
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-246, NCI-2015-00892, NCT02024607
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15246, NCI-2014-02649, I4C-MC-JTBF, NCT02082210
Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188
A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: D4190C00021, NCI-2015-00590, NCT02340975
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CP-MGAH22-05, NCI-2016-00290, NCT02689284
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy before Surgery in Treating Adult Patients with Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 68
Trial IDs: MC1541, NCI-2016-00508, NCT02730546
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1128-CA, NCI-2016-00449, NCT02599324
Docetaxel, Cisplatin, and Fluorouracil in Treating Patients with Gastric or Gastroesophageal Junction Cancer That is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 06-103, NCI-2015-01798, NCT00515411
Proton Beam Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients with Esophageal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-1036, NCI-2012-00078, NCT01512589
Afatinib Dimaleate and Paclitaxel in Treating Patients with Trastuzumab-Refractory Metastatic Esophagus or Stomach Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-166, NCI-2012-00414, NCT01522768
MatriStem Surgical Matrix PSM in Reducing Complications in Patients with Stomach or Esophageal Cancer Undergoing Surgery
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 13-178, NCI-2013-02006, NCT01970306
Ceritinib in Treating Patients with Activated Gastrointestinal Malignancies That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-0802, NCI-2016-00335, NCT02638909
Ramucirumab, Trastuzumab, Capecitabine, and Cisplatin in Treating Patients with Stage IV HER2-Positive Gastroesophageal Junction or Gastric Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-301, NCI-2016-00548, NCT02726399
Pembrolizumab and Palliative Radiation Therapy in Treating Patients with Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16099, NCI-2016-00686, NCT02830594
Combination Chemotherapy and Pembrolizumab in Treating Patients with Previously Untreated Localized Gastric or Gastroesophageal Junction
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AAAQ9871, NCI-2017-00556, NCT02918162
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EMR 100070-001, NCI-2013-02214, 2013-002834-19, NCT01772004
Safety and Tolerability Study in Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: GS-US-296-0101, NCI-2013-01417, NCT01803282
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients with Locally Advanced Gastroesophageal or Stomach Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0594, NCI-2014-02574, NCT02366819
Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HALO-107-101, NCI-2015-01789, NCT02563548
Safety Study of Talimogene Laheraprepvec Injected Into Hepatocellular Carcinoma and Metastatic Liver Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 20140318, NCI-2015-02069, 2014-005386-67, NCT02509507
A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GO30140, NCI-2016-00679, NCT02715531
Start Over